A ntiretroviraltherapyhasimprovedtheprognosis ofpatientswithhumanimmunodeficiencyvirus (HIV)infection (Palellaetal,1998) .Currently, antiretroviral therapy is the only treatment that has demonstratedefficacyforHIV.However,herbalmedicines are widely used by HIV patients to complement conventional therapy. In a cross-sectional study in the UK,61%ofpatientsonantiretroviraltherapyhadused herbal medicines or supplements (Ladenheim et al, 2008) whileinaSouthAfricanstudy,30%ofpatients admitted herbal medicine use (Peltzer et al, 2008) . In western countries, commonly used herbal medicines include garlic, echinacea, aloe, St John's wort and ginseng.Theseremediesarewidelyavailableandaccessible withoutprescriptioninmanycountries.Therefore,cotreatment with antiretroviral therapy may occur, even withouttheknowledgeofHIVclinicians (Peltzeretal, 2008) .
Although herbal medicines are widely used there is inadequate evidence to support their use for HIV treatment. A Cochrane review of eight placebo-controlled randomized trials and one open-label study found insufficient evidence to conclude that the herbalmedicinesstudiedprovidedanybeneficialeffect on HIV treatment outcomes (Liu et al, 2005) . However,lackofefficacyforHIVandtheabsenceof clinically important effects are not synonymous. Becauseherbalmedicinesarelikelytobeco-administered with established HIV treatments (antiretroviral therapy),itisimportanttoevaluatethepotentialrisks andbenefitsofco-treatment.
Herbalmedicinescontainvastnumbersofpharmacologicallyactivecompoundswithpotentialforpharmacokineticinteractionswithawiderangeofpharmaceutical products (Fugh-Berman, 2000) . Pharmacokinetic interactions which reduce antiretroviral drug exposure may increase the risk of selection of resistant strains of HIV and result in therapeutic failure. In contrast, interactions which improve antiretroviral exposure may have therapeutic benefit. However,concentrationsofantiretroviraldrugswhich exceed the therapeutic range may increase the risk of toxicityandunderminepatientadherence (Ladenheim et al, 2008) . Importantly, drug-herbal interactions may be bi-directional and antiretroviral drugs may modifyconcentrationsorefficacyofphytochemicalsin herbalmedicines.
Antiretroviral drugs
HIV is a single-stranded positive-sense ribonucleic acid (RNA) virus which is characterized by a unique replicationpatterninvolvingtranscriptionofdeoxyribonucleic acid (DNA) from viral RNA. The replicationstepsinvolveviralentryintohumancells,reverse transcription of viral RNA, integration of proviral DNA, transcription, translation, viral assembly and release.AntiretroviraltherapyinhibitsHIVreplication by interfering with these steps. But antiretroviral therapy is not curative and lifelong, daily suppressive treatment is standard of care (Joint United Nations Programme on HIV/AIDS and World Health Organization,2009 
Other mechanisms
WhileCYP-mediatedmetabolismplaysthemajorrolein protease inhibitor and non-nucleotide reverse transcriptaseinhibitorelimination,otherpathwaysinvolved in the absorption and elimination of these agents also contribute.
P-glycoprotein is a 170kDa transmembrane protein expressed in cells of the intestine, kidney and bloodbrain barrier. On the luminal surface of enterocytes, P-glycoproteinactsasaneffluxpump,expellingabsorbed drugsbacktothegastrointestinallumen( Figure 1 )and consequently reducing drug bioavailability. P-glycoproteinisatransporterofawidevarietyofcompounds including protease inhibitors (Owen et al, 2005) . For the non-nucleotide reverse transcriptase inhibitors,efavirenzdoesnotappeartobeasubstrateof P-glycoprotein(Jannehetal,2009)butnevirapinestudiesshowedconflictingresults (Brownetal,2008; Janneh et al, 2009 ). Inducers of P-glycoprotein increase its expression in enterocytes, limit gastrointestinal drug absorptionandreduceantiretroviraldruglevelsinblood. Incontrast,P-glycoproteininhibitorswillenhancedrug absorption and consequently increase antiretroviral exposure.
Drug elimination is facilitated by the conversion of non-polar drug and metabolites to more soluble compounds (phase II metabolism). Glucuronidation is the most important pathway for phase II metabolism.Two
Potential for interactions with antiretroviral drugs
Apartfromenfuvirtide,allcurrentlyapprovedantiretroviral drugs are orally administered. Drug interactions mayoccurduringtheprocessesofabsorptionfromthe gastrointestinal tract, drug distribution, drug metabolism and elimination. However, the potential for interactions varies depending on the class of antiretroviral drugs.Thenucleotidereversetranscriptaseinhibitorsare pro-drugs which undergo intracellular phosphorylation duringconversiontotheiractiveforms.Forthesedrugs, intracellularconcentrationsappeartobemoreimportant than plasma concentrations in determining efficacy. Efficacy of raltegravir (an integrase inhibitor) also appearstobedependentonintracellularbindingtothe HIV pre-integration complex rather than plasma drug levels. Consequently, pharmacokinetic interactions involvingdrugconcentrationsinplasmamayhaveonly a minor impact on the efficacy of nucleotide reverse transcriptaseinhibitorsandintegraseinhibitors.
Conversely, the protease inhibitors and non-nucleotidereversetranscriptaseinhibitorshavegreaterpotential fordruginteractions.Thesedrugsaresubstrates,inducers or inhibitors for major drug transporters and drug metabolizing enzymes in the body. Other compounds whichinduceorinhibitthesepathwayscanaltereliminationofproteaseinhibitorsandnon-nucleotidereverse transcriptaseinhibitors.Inhibitionmayinvolvecompetitionbetweenaninhibitorandtheproteaseinhibitoror non-nucleotide reverse transcriptase inhibitor for the active site of the transporter or enzyme. Such interactions tend to occur rapidly and may have clinically important consequences. In contrast, induction is a gradualprocessinvolvingproteinsynthesisofmetabolic enzymesortransportersfollowingprolongedexposureto aninducer.Generally,themaximaleffectofinductionis observed after several weeks. Key pathways influencing antiretroviraleliminationarediscussedbelow.
Cytochrome P450 metabolism
The cytochrome P450 (CYP) enzymes are a group of haemthiolateproteinswhichareresponsibleformetabolism of a wide variety of drugs. These enzymes are locatedonthesmoothendoplasmicreticulumofhepatocytesand,lesscommonly,intheintestinal,brain,kidney andlungcells (Venkatakrishnanetal,2001) .Themajor isoform responsible for metabolism of protease inhibitors is CYP3A4 while non-nucleotide reverse transcriptase inhibitors are metabolized by CYP3A4 and CYP2B6. These enzymes are responsible for phase I metabolismofxenobiotics,aprocesswhichinvolvesthe generation of metabolites which are usually less potent than the parent compound. Clinically significant drug interactions involving protease inhibitors and nonnucleotidereversetranscriptaseinhibitorsarecommonly mediated by induction or inhibition of CYP3A4 and CYP2B6.Inductionleadstolowerdrugconcentrations 
Herbal-antiretroviral interactions
Overall, research on antiretroviral interactions with herbalmedicineshasbeenconstrainedbymethodologicalchallenges.Fewpharmacokineticstudiesareavailable investigating pharmacokinetic interactions between herbalmedicinesandantiretroviraltherapyandmostof thesestudieswereconductedinhealthyvolunteersand notamongHIVpatientswhomayhavemorbiditiesthat alter drug absorption and metabolism. Instead, many dataarederivedfromin-vitrostudiescharacterizingthe effect of herbal medicines on P-glycoprotein and CYP. However, in-vitro studies generally provide limited mechanistic information which may underestimate the contributions from other pathways for drug transport, metabolismandelimination.
In addition, standardization of herbal medicine preparations and dosages is problematic which may diminish the reproducibility of individual studies (MacDonaldetal,2009 ).Hence,herbal-druginteractionadviceisoftenbasedonexpertopinionsupported by low quality evidence. In spite of these limitations, several clinically important interactions have been identified. Information on potential and known antiretroviralinteractionswithherbalmedicinesisavailable on websites such as www.hiv-druginteractions.org (Figure 2) ,butasinformationinthefieldchangesrapidly,aformalcheckwithanHIVpharmacistshouldbe performedineachcaseinordertoensurethatthemost up-to-date information is considered during patient management.
St John's wort
StJohn'swort(Hypericum perforatum)isoneofthemost commonlyusedherbalmedicinesinwesterncountries.It contains several pharmacologically active phytochemicalsincludinghyperforin,biflavonoids,tannins,xanthones, phloroglucinols and napthodianthrones. Patients withHIVmayuseStJohn'swortfortreatingmooddisorderslikedepression.Althoughtheprecisemechanism ofitsantidepressiveeffectisunclear,itispostulatedthat its hyperforin inteferes with neurotransmitter uptake (Hendersonetal,2002) .Inapharmacokineticstudyin eight patients, St John's wort reduced indinavir's area underthecurveby54% (Piscitellietal,2000) ,possibly byinductionofCYP3A4.ThemagnitudeofthisinteractionraisedconcernsthatconcomitantuseofStJohn's wort and protease inhibitors could result in treatment failure. Similarly, St John's wort was found to increase nevirapineclearanceby35%,resultinginlownevirapine plasma concentrations (de Maat et al, 2001 ). Consequently, St John's wort is contraindicated in patients receiving non-nucleotide reverse transcriptase inhibitorsandproteaseinhibitors.
Garlic
Garlic(Allium sativum)isreportedtohaveantimicrobial properties and beneficial effects on the cardiovascular system. In-vitro work demonstrated that garlic is an 
inhibitor of several CYP isoforms including CYP3A4 (Foster et al, 2001 ). However, this finding was contradicted by a subsequent healthy volunteer study using saquinavirasthesoleproteaseinhibitor. Saquinavir exposure was markedly diminished (51% reduction in saquinavir area under the curve) after repeateddosingwithgarlicsupplements (Piscitellietal, 2002) .Thereductioninsaquinavirexposureisprobably explained by CYP3A4 induction following prolonged exposuretogarlicratherthaninhibition.Thus,garlicis contraindicatedinpatientsusingnon-boostedsaquinavir.
Echinacea
Echinaceaistraditionallyusedtoimproveimmunefunction and prevent viral infections such as the common cold.ItisaninducerofCYP3A4andthereforeexpected to lower concentrations of drugs metabolized by this enzyme. However, echinacea did not significantly alter the pharmacokinetics of lopinavir when coadministered withritonavir (Penzaketal,2010) .Theauthorssuggest that the marked inhibitory effect of ritonavir may have overcometheinductiveeffectsofechinaceaonCYP3A4. Untiladditionaldataareavailableforotherboostedprotease inhibitors, it is prudent to monitor patients' antiretroviraltherapyclosely.Echinaceaisaweakinhibitorof UGT1A1anditisnotexpectedtohaveclinicallysignifi-cant consequences on metabolism of substrates of UGT1A1(MohamedandFrye,2011).
Milk thistle
Purportedly,milkthistlehasbeneficialeffectsontheliver anditistraditionallyusedtomanagediseaseslikehepatitisandlivercirrhosis.Inhealthyvolunteers,indinavir's pharmacokinetic parameters were not significantly reducedfollowing4weeksofmilkthistleadministration. However,laboratorystudiesdemonstratedthatmilkthistlehaspotentialtoinhibitCYP (MacDonaldetal,2009) and glucuronyltransferases including UGT1A1 and UGT2B7 (MohamedandFrye,2011) .Hencecautionis advised when using milk thistle with non-nucleotide reversetranscriptaseinhibitorsorproteaseinhibitors.
African herbal medicines
Herbal medicines in Africa are numerous and greatly variedreflectingmarkedgeographicalandculturaldiversityonthecontinent.Theseplantsarecommonlyusedto meet primary health-care needs in regions with limited formalhealthservices.Inanethnobotanicalsurvey,investigators identified 103 medicinal plants used for treatment of HIV-related ailments and opportunistic infectionsinUgandaalone (Lamordeetal,2010) .Although, African herbal medicines are numerous, little is known aboutthepotentialforinteractionsforthevastmajority ofplants.Thisknowledgegapcomplicateseffortstointegrate herbal medicines into national health systems already stretched by the HIV pandemic. In-vitro data fromtwopopularSouthAfricanplants(Hypoxis hemerocallideaandSutherlandia)demonstratesthatinteractions are indeed possible. H. hemerocallidea and Sutherlandia were not only shown to inhibit CYP3A4 and P-glycoprotein in a microsome-based assay, but also to activatethenuclearreceptorresponsibleforCYP3A4and P-glycoprotein induction (Mills et al, 2005) . Consequently,theuseoftheseherbsshouldbeavoided with protease inhibitors or non-nucleotide reverse transcriptaseinhibitors.
Clinical approach to herbal interactions
The management of herbal antiretroviral interactions is challenging because of the large number of pharmacologicallydistinctherbalmedicineswhicharebeingused inthecontextofsteadilyincreasingnumberofantiretroviral drugs. Patients may not spontaneously disclose herbal medicine use so clinicians should adopt a direct questioning approach to obtain this history (LangloisKlassenetal,2008; Liuetal,2009 
KEY POINTS
n Herbal medicines are popular and co-treatment with antiretroviral therapy is common. n Drug disposition of protease inhibitors and non-nucleoside reverse transcriptase inhibitors is influenced by cytochrome P450 and P-glycoprotein resulting in a significant potential for herbal-antiretroviral interactions. n Clinicians should actively inquire about use of herbal medicines among HIV patients. n When herbal medicine use is identified, a HIV pharmacist should be consulted to conduct a formal check for herbal-antiretroviral interactions. n Herbal-antiretroviral interactions do occur but are often manageable if correctly identified.
